72% of trial patients administered Enherthu showed no progression in their cancer after 12 months, compared to 34.1% of those treated with the current standard of care medication
Risk of some cancers may be reduced by boosting production of a single enzyme in the body, which in turns keeps BRD4 protein in check, say Ben Gurion University scientists
Rambam Medical Center apologizes after report reveals that for 1.5 years in 2016-7, dates were forged on medicines set to be destroyed and then given to patients, including kids
Israeli researchers discover specific type of white blood cells thatcan be engineered to attack solid tumors, with fewer side effects than chemotherapy
Recent comments